LGT Capital Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

LGT Capital Partners’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-55,000	Closed	-$284K	–	61
2024 Q2	$284K	Hold	55,000	–	–	0.01%	58
2024 Q1	$294K	Hold	55,000	–	–	0.01%	57
2023 Q4	$428K	Hold	55,000	–	–	0.01%	60
2023 Q3	$217K	Hold	55,000	–	–	0.01%	63
2023 Q2	$173K	Hold	55,000	–	–	0.01%	64
2023 Q1	$147K	Hold	55,000	–	–	﹤0.01%	65
2022 Q4	$197K	Hold	55,000	–	–	0.01%	63
2022 Q3	$354K	Hold	55,000	–	–	0.01%	66
2022 Q2	$529K	Buy	55,000 +5,000	+10%	+$46.8K	0.02%	65
2022 Q1	$595K	Hold	50,000	–	–	0.02%	70
2021 Q4	$1.63M	Buy	50,000 +45,661	+1,052%	+$1.85M	0.04%	72
2021 Q3	$194K	Buy	+4,339	New	+$212K	0.01%	73

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

LGT Capital Partners's SYRS Position: Q3 2024 in Review

LGT Capital Partners sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 55,000 shares — an estimated $284K sold.

LGT Capital Partners first reported a position in SYRS in Q3 2021 and held it in 12 quarters. The position peaked at $1.63M in Q4 2021. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

LGT Capital Partners reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
LGT Capital Partners sold 55,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $284K.
LGT Capital Partners first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
LGT Capital Partners's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.63M in Q4 2021.
65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on LGT Capital Partners's 13F filing for Q3 2024, filed 8 Nov 2024.